Vas Narasimhan, Novartis CEO (Simon Dawson/Bloomberg via Getty Images)
Two decades after Gleevec approval, Novartis scores new CML OK for 'wild card' STAMP inhibitor
One of the latest additions to Vas Narasimhan’s “wild card” drug list has delivered.
Scemblix, as asciminib will be marketed, will be the first …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
